Explore the vast range of titles available.

Introduction Cancer is a significant worldwide health problem, and targeted drugs like Cabozantinib and Atezolizumab offer new therapeutic options. These drugs enhance patient survival by specifically targeting cancer cells while minimizing damage to healthy tissues. The current research investigates the effectiveness of employing the combination of Cabozantinib and Atezolizumab vs single-agent Cabozantinib. Methods In this study, we searched databases including PubMed/Medline, Scopus, Embase, Cochrane, and Web of Science up to the end of January 2025. The results were categorized into two groups: the intervention group (Cabozantinib plus Atezolizumab) and the control group (Cabozantinib monotherapy) in cancer patients. We evaluated variables such as efficacy outcomes, including Objective Response Rate (ORR) and Disease Control Rate (DCR), as well as adverse events (safety). Data analysis was performed using random-effects models, and Relative Risk (RR) was reported as the effect size. Results Three clinical trials were included in this study. Regarding efficacy outcomes, there was no statistically significant difference in ORR between the intervention group and the control group (RR = 1.11, 95% CI: 0.76-1.61). Similarly, DCR did not differ significantly between groups (RR = 0.98, 95% CI: 0.94-1.03). In terms of safety, the combination therapy was associated with a statistically significant reduction in four treatment-related adverse events: diarrhea (RR = 0.91, 95% CI: 0.83-0.99), nausea (RR = 0.79, 95% CI: 0.65-0.95), vomiting (RR = 0.70, 95% CI: 0.52-0.96), and hypokalemia (RR = 0.28, 95% CI: 0.19-0.40). Conclusion The findings suggest that the combination of Cabozantinib and Atezolizumab does not offer significant improvement in treatment efficacy compared to Cabozantinib alone. However, the combination may be associated with a lower incidence of certain chemotherapy-related adverse events. These exploratory findings may inform future research on treatment strategies for patients who experience intolerance to Cabozantinib monotherapy. Plain Language Summary Cancer treatment often involves using drugs that target the cancer cells, but these treatments can come with side effects. One such treatment is Cabozantinib, which is approved for several types of cancer. Recently, it has been tested with a second drug, Atezolizumab, to see if the combination could be more effective in treating cancer and also reduce side effects. In our study, we looked at research from three clinical trials that compared Cabozantinib alone to the combination of Cabozantinib and Atezolizumab. We wanted to understand if adding Atezolizumab would improve treatment results, like how many patients' cancer shrank or stopped growing (this is called the Objective Response Rate, or ORR) and how well the disease was controlled (the Disease Control Rate, or DCR). We also looked at the side effects of these treatments. The combination therapy did not show a clear improvement in shrinking or controlling the cancer compared to Cabozantinib alone. However, the combination therapy did lead to fewer side effects, such as nausea, vomiting, diarrhea, and low potassium levels, making it a better option for patients who struggle with these side effects from Cabozantinib alone. Our findings suggest that while the combination treatment may not be better at treating cancer, it could be a good choice for patients who cannot tolerate Cabozantinib on its own. More research is needed to better understand who might benefit the most from this combination therapy, especially for patients with certain types of tumors.

Background Mifepristone has demonstrated favorable effects in managing uterine myomas, particularly for patients aiming to preserve fertility. This study evaluates the effect of Mifepristone on uterine parameters, including uterine volume and endometrial thickness, across different dosages. Methods A systematic review and meta-analysis were conducted by searching PubMed, Web of Science, Scopus, Embase, Cochrane Library, and clinical trial registries up to November 30, 2024. Eligible studies were randomized controlled trials (RCTs) comparing Mifepristone with placebo, other drugs, or different Mifepristone dosages in patients with uterine myoma. The primary outcomes were changes in uterine volume and endometrial thickness. Secondary outcomes included symptom relief, such as dyspareunia. Data were pooled using a random-effects model, and effect sizes were expressed as standardized mean differences (SMD) or relative risks (RR) with 95% confidence intervals (CI). Results Fourteen RCTs involving a total of 1260 patients were included. Higher doses of Mifepristone (10 mg daily) compared to lower doses (5 mg daily) were associated with greater, albeit non-significant, reductions in uterine volume (SMD: -0.08, 95% CI: -0.25 to 0.09, p  = 0.35) and a non-significant increase in endometrial thickness (SMD: 0.22, 95% CI: -0.23 to 0.66, p  = 0.34). The 10 mg dose was significantly more effective in resolving dyspareunia (RR: 1.87, 95% CI: 1.59 to 2.20, p  < 0.01). Conclusion Our analysis indicated that Mifepristone was associated with a non-significant reduction in uterine volume among patients with uterine myoma. However, higher daily doses (10 mg) demonstrated greater clinical benefits in relieving dyspareunia, despite minimal changes in uterine size. These findings suggest that higher doses (10 mg daily) may be a consideration for symptom relief, particularly for dyspareunia, despite minimal changes in uterine size. This suggestion is preliminary, given the non-significant primary outcomes and low certainty of evidence for key comparisons.

Hepatic hydatid disease, a manifestation of cystic echinococcosis caused by , remains endemic in many regions and poses a persistent therapeutic challenge. Although surgery is often employed for definitive management, recurrence, procedural risks, and anatomical constraints have led to growing interest in minimally invasive alternatives such as percutaneous aspiration and endoscopic interventions. We report a 52-year-old male with an incidentally detected hepatic hydatid cyst who initially underwent surgical cystectomy and cholecystectomy. Twenty-five days postoperatively, the patient developed new abdominal fullness, and repeat imaging revealed a cystic lesion in the left hepatic lobe measuring 13.4 × 9.9 cm, reported radiologically as recurrence. The patient underwent endoscopic ultrasound (EUS)-guided fine-needle aspiration and lavage of the cyst cavity with 20 mL of 96% ethanol. The procedure was well tolerated with no adverse events, and follow-up imaging at 6 months confirmed complete cyst resolution. This case demonstrates the technical feasibility and clinical safety of EUS-guided ethanol ablation as a minimally invasive alternative for recurrent hepatic hydatid cysts. It highlights the expanding therapeutic potential of EUS beyond conventional indications and supports further exploration of this technique in selected cases.

Background Cervical cancer (CC) remains the fourth most prevalent malignancy among women globally, with a disproportionate burden in low‐ and middle‐income countries, where it is often diagnosed at advanced or metastatic stages. Aims Despite an increasing number of case reports and institutional studies on brain metastases (BMs) arising from CC, current understanding of their epidemiology, clinical presentation, and prognostic implications remains fragmented and lacks comprehensive synthesis. Methods We executed a systematic and unrestricted search of five major databases, PubMed/Medline, Scopus, Embase, Web of Science, and Google Scholar, covering all records up to April 19, 2025. Studies were eligible for inclusion if they provided a clear report on the incidence of BMs among CC patients. The quality and risk of bias of the selected studies were independently appraised using the Joanna Briggs Institute (JBI) assessment criteria. For statistical analysis, we utilized STATA version 17, implementing random‐effects meta‐analytical models to estimate the aggregated incidence along with corresponding 95% confidence intervals (CIs). Results A total of 17 studies encompassing 33 datasets were included in the final analysis. The global pooled incidence of BMs among cervical cancer patients was estimated at 0.65% (95% CI: 0.46–0.85). Incidence was highest in Turkey (1.83%, 95% CI: 0.91–2.75) and lowest in South Africa (0.22%, 95% CI: 0.0–0.47). Among histologic subtypes, neuroendocrine carcinoma exhibited the highest pooled incidence of BMs at 10.60% (95% CI: 0.0–21.63), followed by adenocarcinoma at 0.89% (95% CI: 0.14–1.64). The pooled mean survival time following the diagnosis of BMs was 6.80 months (95% CI: 5.08–8.52), while the mean interval from the initial cervical cancer diagnosis to the development of BMs was 28.15 months (95% CI: 24.27–32.03). Conclusion Although BMs in cervical cancer are rare, they are associated with dismal survival outcomes and poor prognosis. These findings underscore the importance of vigilant surveillance in high‐risk patients and may inform the development of more targeted and effective therapeutic and preventive strategies.

Objective Stroke is a leading cause of death and disability worldwide, with its prevalence increasing due to risk factors such as hypertension, diabetes, and hyperlipidemia. Pregnancy-related stroke (PRS), a severe pregnancy complication, particularly during the postpartum period, has shown rising incidence rates, occurring at 30 per 100,000 pregnancies, three times higher than in the general young adult population. This study systematically reviews and analyzes global and regional data regarding the incidence and risk factors of PRS. Methods Comprehensive searches of PubMed/MEDLINE, Scopus, EMBASE, and Web of Science databases were performed until December 20, 2024. Studies reporting any type of stroke occurring during pregnancy (from the time of confirmation to one year postpartum) were included. Study quality was evaluated using the Joanna Briggs Institute (JBI) checklist, and data analysis was conducted with STATA version 17. A random-effects meta-analysis was employed to calculate pooled incidence rates per 100,000 pregnancies, with 95% confidence intervals (CIs). Heterogeneity was assessed using Cochran’s Q test and quantified with the I² statistic. Risk factors for PRS were also evaluated using univariate regression. Results A total of 33 studies involving 270,136,827 pregnant women from 10 countries met inclusion criteria. The global cumulative incidence of PRS was 25.38 (95% CI: 21.02–30.63) per 100,000 pregnancies. Regional analysis revealed the highest incidence in the South-East Asia region (66.31; 95% CI: 44.22–99.42) and the lowest in the European region (12.88; 95% CI: 7.73–21.46). Based on 22 included studies, the pooled maternal mortality rate due to PRS was estimated at 1.55 per 100,000 pregnancies (95% CI: 1.04–2.32). Risk factors significantly associated with PRS included migraine, dyslipidemia, alcohol use, tobacco smoking, sickle cell disorders, coagulopathy, cardiovascular diseases, preeclampsia/eclampsia/gestational hypertension, and postpartum hemorrhage. Conclusion PRS, with a global incidence of 25.38 per 100,000 pregnancies, remains a critical health concern, particularly in regions with limited resources. However, a lack of data from many countries limits a comprehensive global understanding. The identification of key risk factors, such as preeclampsia, cardiovascular disorders, and postpartum hemorrhage, highlights the need for targeted preventive strategies. Improved data collection, early detection, and timely intervention are essential to reducing the burden of PRS worldwide. Trial registration The PROSPERO registration code is CRD420251152299.

Background The integration of immune checkpoint inhibitors with anti-angiogenic therapy has transformed the management of advanced malignancies. Atezolizumab (ATZ), a PD-L1 inhibitor, combined with Bevacizumab (BEV) and chemotherapy, may exert synergistic antitumor effects via immune activation and vascular normalization. However, the comparative efficacy and safety of this triplet regimen across cancer types remain uncertain. Methods A systematic search of PubMed, Embase, Scopus, the Cochrane Library, and major clinical trial registries was conducted from inception to July 31, 2025, to identify randomized controlled trials (RCTs) evaluating ATZ + BEV + chemotherapy versus BEV + chemotherapy alone. Primary endpoints included objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS). Safety outcomes encompassed all-grade and grade III-IV adverse events based on CTCAE. Pooled risk ratios (RRs) and hazard ratios (HRs) were calculated using a random-effects model. Evidence certainty was assessed via GRADE. Results A total of eight RCTs comprising 3707 participants were analyzed. Incorporation of ATZ into the treatment protocol led to a notable increase in ORR (RR = 1.10; 95% CI: 1.00–1.21) and produced significant gains in both PFS (adjusted HR = 0.73; 95%CI: 0.63–0.84) and OS (adjusted HR = 0.83; 95%CI: 0.76–0.92). In contrast, changes in DCR were modest and did not achieve statistical significance (RR = 1.02; P  = 0.324). The addition of ATZ did not substantially elevate the frequency of most adverse events relative to BEV plus chemotherapy alone. However, a statistically significant increase was observed in diarrhea (RR = 1.24; 95%CI: 1.06–1.46), predominantly driven by low-grade events, and in grade III-IV nausea (RR = 1.66; 95%CI: 1.03–1.84). Rates of other grade III-IV toxicities were generally comparable between treatment groups. Sensitivity analyses and assessments for publication bias supported the stability of the results, and the overall certainty of the evidence was judged to be high. Conclusion The ATZ + BEV + chemotherapy regimen demonstrated OS benefits in multiple malignancies, although the magnitude of benefit appears to vary across tumor types. Toxicity was generally manageable, although selective increases in low-grade gastrointestinal events and grade III-IV nausea were observed. Immune-related adverse event profiles differed among indications. These findings support the biologic rationale for concurrent immune and angiogenic targeting; however, tumor-specific factors should be considered when integrating this strategy into contemporary oncology practice. Future biomarker-driven studies are warranted to refine patient selection and optimize therapeutic sequencing.

Background Cervical cancer remains a major malignancy among women, with poor survival rates below 20% despite advances in care. Patients with cervical cancer are most likely to develop hematogenous metastases in the liver, followed by the lungs and bones. Although less commonly involved than other organs, the liver is associated with the poorest prognosis among metastatic sites. This study aims to estimate the global incidence of liver metastasis in cervical cancer patients and explore its clinicopathological characteristics. Methods This is a systematic review and meta-analysis conducted to assess the global incidence and clinicopathological characteristics of liver metastasis in cervical cancer patients. The review followed PRISMA guidelines, and a comprehensive search was performed in Embase, PubMed, Web of Science, Scopus, and Google Scholar up to February 28, 2025. Eligibility criteria included studies that explicitly reported the incidence of liver metastases following a diagnosis of cervical cancer, and provided data on both total cervical cancer cases and cases with liver metastases. Exclusion criteria were studies lacking clear incidence data, case reports, reviews, or studies not specific to cervical cancer. The pooled incidence was calculated using a random-effects model implemented in STATA version 17, based on raw proportions. Results were presented with 95% confidence intervals (CI), and heterogeneity was assessed using the I² statistic. Results Out of an initial 7508 articles identified across five databases, 11 studies (comprising 20 records) met the eligibility criteria and were included in the final analysis. The global pooled incidence of liver metastasis among cervical cancer patients was estimated at 1.88% (95% CI: 1.27–2.48). To explore variability among populations, we conducted subgroup analyses based on development indices. Countries with a very high Human Development Index (HDI) reported a higher incidence (2.12%, 95% CI: 1.40–2.84) than those with high (1.96%, 95% CI: 0.98–2.94) and medium (0.75%, 95% CI: 0.0–1.57) HDI levels. The incidence of liver metastasis in combination with metastases to other organs was nearly three times greater (1.76%, 95% CI: 0.99–2.53) than that of isolated liver metastasis. Furthermore, in a subgroup analysis based on histological subtype, the highest pooled incidence was observed in patients with cervical adenocarcinoma (2.36%, 95% CI: 1.35–3.37). Conclusion This meta-analysis demonstrates that while liver metastasis in cervical cancer is relatively rare, its occurrence appears more frequently in patients with advanced disease. These results underscore the need for routine liver screening in high-risk patients and support the refinement of therapeutic strategies.